The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world clinical outcomes and economic burden of early discontinuation of taxane therapy among patients with metastatic castration-resistant prostate cancer.
 
Jeetvan Patel
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Jennifer Nguyen
Employment - Novartis
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Novartis
 
Vamsi Bollu
Employment - Novartis
Stock and Other Ownership Interests - Novartis
Other Relationship - Novartis
 
Barinder Kang
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Amrita Sawhney
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Clare Byrne
Consulting or Advisory Role - Novartis paid Asclepius Anaytics to consult/perform study
Research Funding - Novartis funded the conduct of this study
 
Jackson Tang
Consulting or Advisory Role - N-of-One
Research Funding - Novartis funded the conduct of this study
 
Magdaliz Gorritz
Research Funding - Amgen (Inst); AstraZeneca (Inst); Lilly (Inst); Novartis (Inst); Otsuka (Inst); Takeda (Inst); Travere Therapeutics (Inst)
 
Chi-Chang Chen
Research Funding - I am an emplyee of IQVIA which Novartis hired to conduct part of current stud
 
Neal D. Shore
Employment - GenesisCare
Leadership - Alessa Therapeutics; Photocure
Stock and Other Ownership Interests - Alessa Therapeutics; Photocure
Consulting or Advisory Role - Abbvie; Accord Research; AIkido Pharma; Amgen; Antev; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; Aura Biosciences; Bayer; Bioprotect; Bristol-Myers Squibb/Sanofi; CG Oncology; Clarity Pharmaceuticals; Dendreon; Exact Imaging; FerGene; Ferring; Fize Medical; Genesis Cancer Care; Genzyme; InVitae; Janssen Scientific Affairs; Lantheus Medical Imaging; Lilly; MDxHealth; Medivation/Astellas; Merck; Minomic; Myriad Genetics; Novartis; Peerview; Pfizer; Photocure; PlatformQ Health; Promaxo; Propella Therapeutics; Protara Therapeutics; Sanofi; Speciality Networks; Sumitomo Pharma Oncology; Telix Pharmaceuticals; Tolmar; Urogen pharma
Research Funding - Abbvie; Advantagene; Amgen; Aragon Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Pfizer; CG Oncology; Clovis Oncology; Dendreon; DisperSol; Endocyte; Exact Imaging; Exelixis; Ferring; FKD Therapies; FORMA Therapeutics; Foundation Medicine; Genentech; Guardant Health; InVitae; Istari Oncology; Janssen; Jiangsu Yahong Meditech; MDxHealth; Medivation; Merck; MT Group; Myovant Sciences; Myriad Genetics; Novartis; Nymox; OncoCellMDx; ORIC Pharmaceuticals; pacific edge; Palette Life Sciences; Pfizer; Plexxikon; POINT Biopharma; Propella Therapeutics; Propella Therapeutics; RhoVac; Sanofi; SeaGen; Sesen Bio; Steba Biotech; Theralase; Tolmar; Urogen pharma; Urotronic; US Biotest; Vaxiion; Veru; Zenflow
Expert Testimony - Ferring